This multiregional , double-blind study randomized 557 patients with T2DM ( mean glycated hemoglobin [ HbA1c ] , 6.9 % ) , previously treated with metformin and any sulfonylurea to receive either vildagliptin ( 50 mg twice daily ) or gliclazide plus metformin .